

Inpatient Antibiogram 2022- Urine Source only

Gram Negative-Urine Only

Organisms	Aminoglycosides			Beta lactam/Beta lactam Inhibitors			Carbapenems			Cephalosprin Class			Fluoroquinolones			Folate pathway inhibitor			Monobactams		
	Amikacin	Gentamicin	Tobramycin	Amoxicillin/Clavulanate	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Ertapenem	Meropenem	Cefazolin	Cefazolin Urine	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole)	Fosfomycin	Aztreonam	Nifurofutoin	
<i>Citrobacter freundii</i> complex (22)	90	90	0	0	0	81	100	100	0	77	72	81	81	90	77						
<i>Enterobacter cloacae</i> complex (46)	93	89	0	0	0	76	88	100	0	69	66	86	89	82							30
<i>Escherichia coli</i> (1263)	94	94	88	62	66	98	99	100		95		99	99	77	84	81	100				98
<i>Escherichia coli</i> , ESBL (117)	65	57					97	99						12	24	50	99				94
<i>Klebsiella oxytoca</i> (2)	100	100	100	0	0	100	100	100	0	100	100	100	100	100	100	100					100
<i>Klebsiella pneumoniae</i> (169)	99	98	96	0	88	95	99	100		98		99	100	92	94	94					44
<i>Proteus mirabilis</i> (134)	95	92	94	80	91	99	99			90		97	97	81	83	88					0
<i>Pseudomonas aeruginosa</i> (89)	98	96	97			91		92		91	93		76	77			85				
<i>Citrobacter koseri</i> (35)	100	100	100	0	91	97	100	100	88			100	100	97	97	100					51
<i>Klebsiella aerogenes</i> (36)	97	94	0	0	0	77	97	100	0			80	80	94	94	94					38
<i>Klebsiella oxytoca/Raoultella ornithinolytica</i> (57)	94	94	92	0	47	94	100	100	26			96	91	89	96	87					89
<i>Klebsiella pneumoniae</i> ESBL (8)		75	50					100	100					12	37	0					50
<i>Klebsiella variicola</i> (10)	100	100	100	0	90	90	100	100	90			100	100	100	100	100					70
<i>Morganella morganii</i> (16)	100	100	0	0	43	100	100	100	0			87	100	81	81	81					0

Cefazolin predicts results for the oral agents-Cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil and loracarbef when used for therapy of uncomplicated UTI's due to *E. coli*, *K. pneumoniae*, and *P. mirabilis*.
A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only.

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.

2. Isolate counts are in parenthesis to the right of the organism name.

3. MRSA (Methicillin Resistant Staph aureus): In 2022, 144 out of 516 (30.0%) Staph aureus were MRSA.

Prior years were as follows: 2021-30.3%, 2020-30.0%, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 - 52.5%.

4. ESBL (Extended Spectrum Beta Lactamases): In 2022, 263 out of 3,088 (8.5%) were ESBL (combined inpatient and outpatient).

Prior years were as follows: 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.

5. Penicillin Resistant Streptococcus pneumoniae: In 2022 no Penicillin Resistant Streptococcus pneumoniae.

Prior year were as follows: 2021 and 2020-No Penicillin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Inpatient Antibiogram 2022- Urine Source only

Gram positive-Urine only

Organisms	Tetracycline	Doxycycline	Gentamicin	Aminoglycosides	Rifampin	Ampicillin	Oxacillin	Beta lactam/Beta lactam inhibitors	Cephalosporin Class	Levofloxacin	Fluoroquinolones	Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole)	Folate pathway inhibitor	Vancomycin	Glycopeptides	Daptomycin	Lipopeptides	Nitrofurantoin	Nitrofurans	Linezolid	Oxazolidinones
Enterococcus faecalis (198)	23					99				92			100			99	99				
Enterococcus faecium (8)	50					50				62			87	100						87	
Staphylococcus epidermidis (27)	84	85	100	100		38	42	65				100	100	100	100	100	100	100	96		
Staphylococcus aureus (37)	97	97	100	100		100	100	83		100		100	100	100	100	100	100	100	100	100	
Methicillin resistant Staphlococcus aureus (15)	66	86	100	93		0	0	13		93	100	100	100	100	100	100	100	100	100	100	

A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only.

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.
2. Isolate counts are in parenthesis to the right of the organism name.
3. MRSA (Methicillin Resistant Staph aureus): In 2022, 144 out of 516 (30.0%) Staph aureus were MRSA.
Prior years were as follows: 2021-30.3%, 2020-30.0 %, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 -52.5%.
4. ESBL (Extended Spectrum Beta Lactamases): In 2022, 263 out of 3,088 (8.5%) were ESBL (combined inpatient and outpatient).
Prior years were as follows: 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
5. Penicilllin Resistant Streptococcus pneumoniae: In 2022 no Penicilllin Resistant Streptococcus pneumoniae.
Prior year were as follows: 2021 and 2020-No Penicilllin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicilllin resistant.

Inpatient Antibiogram 2022- Non Urine Source only

Gram Negative -Non-Urine Only	Aminoglycosides			Beta lactam/Beta lactam inhibitors			Carbapenems			Cephalosporin Class			Fluoroquinolones			Folate pathway inhibitor		Monobactams	
	Amikacin	Gentamicin	Tobramycin	Amoxicillin/Clavulanate	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Ertapenem	Imipenem	Meropenem	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole)	Aztreonam	
Organisms																			
<i>Citrobacter freundii</i> complex (35)		94	94	0	0	2	88	100		100	0		82	80	82	82	94		
<i>Enterobacter cloacae</i> complex (77)		96	93	0	0	0	80	91		100	0		76	75	90	93	88		
<i>Escherichia coli</i> (1376)		94	94	88	62	66	98	99	100	100	82		98	99	77	84	81	100	
<i>Escherichia coli</i> , ESBL (128)								97		99									
<i>Klebsiella oxytoca</i> (3)		100	100	100	0	33	100	100		100	0		100	100	100	100	100		
<i>Klebsiella pneumoniae</i> (229)		99	97	95	0	85	96	99		100	88		99	100	91	94	93	100	
<i>Proteus mirabilis</i> (163)		95	91	93	80	90	98	99			0		98	98	82	84	88		
<i>Pseudomonas aeruginosa</i> (170)	98	97	98				91		80	92		91	94		78	79		85	
<i>Citrobacter koseri</i> (37)		100	100	100	0	89	97	100		100	86		100	100	97	97	100		
<i>Klebsiella aerogenes</i> (50)		98	96	0	2	2	74	97		100	2		76	76	98	98	96		
<i>Klebsiella oxytoca/Raoultella ornithinolytic</i> (85)		96	95	91	0	50	96	100		100	23		97	94	92	97	91		
<i>Klebsiella pneumoniae</i> ESBL (12)								100		100									
<i>Klebsiella variicola</i> (17)		100	100	100	0	94	94	100		100	94		100	100	94	94	94		
<i>Morganella morganii</i> (25)		100	100	0	0	44	100	95		100	0		92	100	84	84	80		

A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only.

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.
 2. Isolate counts are in parenthesis to the right of the organism name.
 3. MRSA (Methicillin Resistant Staph aureus): In 2022, 144 out of 516 (30.0%) Staph aureus were MRSA.
Prior years were as follows: 2021-30.3%, 2020-30.0 %, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 -52.5%.
 4. ESBL (Extended Spectrum Beta Lactamases): In 2022, 263 out of 3,088 (8.5%) were ESBL (combined inpatient and outpatient).
Prior years were as follows: 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
 5. Penicillan Resistant Streptococcus pneumoniae: In 2022 no Penicillan Resistant Streptococcus pneumoniae.
- Prior year were as follows: 2021 and 2020-No Penicillan Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillan resistant.

Inpatient Antibiogram 2022-Non Urine Source only

Gram positive- Non Urine Only

Organisms	Tetracycline	Doxycycline	Gentamicin	Aminoglycosides	Rifampin	Ampicillin	Beta lactam/Beta lactam inhibitors	Cephalosprin Class	Fluoroquinolones	Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole)	Vancomycin	Glycopeptides	Lincosamides	Lipopeptides	Oxazolidinones	
Enterococcus faecalis (80)			0	85		100					100			94	100	
Staphylococcus epidermidis (57)	74	80	100		96		40	42		67		98	66	100	94	
Staphylococcus aureus (281)	95	98	100		99		100	100		86	97	100	78	100	100	
Methicillin Resistant Staphylococcus aureus	76	95	100		99		0	0	98	35	93	100	65	100	100	

A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only.

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.

2. Isolate counts are in parenthesis to the right of the organism name.

3. MRSA (Methicillin Resistant Staph aureus): In 2022, 144 out of 516 (30.0%) Staph aureus were MRSA.

Prior years were as follows: 2021-30.3%, 2020-30.0 %, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 -52.5%.

4. ESBL (Extended Spectrum Beta Lactamases): In 2022, 263 out of 3,088 (8.5%) were ESBL (combined inpatient and outpatient).

Prior years were as follows: 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.

5. Penicilllin Resistant Streptococcus pneumoniae: In 2022 no Penicilllin Resistant Streptococcus pneumoniae.

Prior year were as follows: 2021 and 2020-No Penicilllin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicilllin resistant.